{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:23:27Z","timestamp":1791228207948,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This pooled analysis of randomized controlled studies investigated the safety and efficacy of onabotulinumtoxinA in male and female patients with overactive bladder (OAB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were pooled from four similarly designed trials in North America and Europe. Adults with idiopathic OAB for \u22656 months inadequately managed by at least one anticholinergic were randomized 1:1 or 2:1 to receive onabotulinumtoxinA 100 U or matched placebo in Cycle 1 and could request open\u2010label retreatment with onabotulinumtoxinA 100 U at \u226512 weeks. Efficacy outcomes at Week 12 included the primary endpoint of mean urinary incontinence (UI) episodes per day and other variables, such as the proportion of patients with \u226550% reduction in daily UI episodes. Safety was assessed by monitoring treatment\u2010emergent adverse events (TEAEs). Analyses by sex were descriptive. Males were further analyzed by benign prostatic hyperplasia (BPH) diagnosis status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the pooled population (<jats:italic>N<\/jats:italic>\u2009=\u20091564), there were 194 males (12.4%) and 1370 females (87.6%). Mean number of baseline UI episodes per day was 4.9 in males and 5.5 in females. At Week 12, numerically greater mean reductions from baseline in number of daily UI episodes were observed with the onabotulinumtoxinA 100 U group (females: \u22123.0; males: \u22122.2) versus placebo (females: \u22121.1; males: \u22121.3). Achievement of \u226550% reduction in daily UI episodes was numerically greater with onabotulinumtoxinA 100 U (females: 64.8%; males: 61.2%) versus placebo (females: 30.6%; males: 44.8%), and numerically higher in males without BPH (onabotulinumtoxinA: 65.1%; placebo: 50.9%) versus with BPH (onabotulinumtoxinA: 54.3%; placebo: 36.6%). A total of 34.7% of males and 39.4% of females experienced at least one TEAE in the first 12 weeks during treatment Cycle 1. Urinary tract infection rate was 13.1% in females and 4.2% in males; incidence of hematuria was 6.8% in males and 1.1% in females. Incidence of urinary retention (defined as incomplete emptying, requiring catheterization) was 2.7% in females and 4.7% in males.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>OnabotulinumtoxinA 100 U was efficacious and well tolerated in men and women with OAB, including in males with and without BPH. No new safety findings were identified when data were analyzed by sex.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.25538","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T05:26:16Z","timestamp":1720416376000},"page":"1765-1775","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: A pooled analysis"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1390-7053","authenticated-orcid":false,"given":"Victor W.","family":"Nitti","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Kohan","sequence":"additional","affiliation":[{"name":"Advanced Urology Center of New York New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"McCammon","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-6703","authenticated-orcid":false,"given":"Brenda","family":"Jenkins","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5303-7992","authenticated-orcid":false,"given":"Kimberly Becker","family":"Ifantides","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Yushmanova","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2960-9931","authenticated-orcid":false,"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.08.039"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_11_3_2","unstructured":"discussion1314\u20101315."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"issue":"1","key":"e_1_2_11_6_1","first-page":"2","article-title":"Gender differences in overactive bladder","volume":"23","author":"Eapen RS","year":"2016","journal-title":"Can J Urol"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-009-0976-9"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2012.04.004"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24348"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23276"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.025"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.01.004"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287217742837"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","unstructured":"CameronAP ChungDE DielubanzaEJ et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder.2024. Accessed May 15 2024.https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/idiopathic-overactive-bladder","DOI":"10.1097\/JU.0000000000004074"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562872211039034"},{"key":"e_1_2_11_16_1","unstructured":"GormleyEA LightnerDJ BurgioKL et al. Diagnosis and treatment of overactive bladder (non\u2010neurogenic) in adults: AUA\/SUFU guideline.2019. Accessed February 10 2023.https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/overactive-bladder-(oab)-guideline"},{"key":"e_1_2_11_17_1","unstructured":"HardingCK LapitanMC ArlandisS et al.EAU guidelines on management of non\u2010neurogenic female lower urinary tract symptoms.European Association of Urology;2023."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.04.001"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.069"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000914"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.05.033"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00454-3"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-018-0204-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02962-z"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147137"},{"key":"e_1_2_11_27_1","volume-title":"Botox [package insert]","year":"2021"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2023.09.013"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24871"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173922.29275.54"},{"key":"e_1_2_11_30_2","unstructured":"discussion1321\u20101322; author reply 1322."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.03.146"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13479"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-017-3271-1"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.UTI-0002-2012"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-6349.2004.00296.x"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2018.1551871"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a008958"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.25538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:39:25Z","timestamp":1757911165000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.25538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/nau.25538"],"URL":"https:\/\/doi.org\/10.1002\/nau.25538","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"2024-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}